NVO - Novo Nordisk A/S

Novo Nordisk A/S

Novo Alle
Bagsvaerd 2880
Denmark
45 44 44 88 88
http://www.novonordisk.com

Sector: Healthcare
Industry: Biotechnology
Full-time employees: 43,158

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Lars Fruergaard Jørgensen	Pres, CEO & Member of Management Board	N/A	N/A	1966
Mr. Karsten Munk Knudsen	Exec. VP, CFO & Member of the Management Board	N/A	N/A	1971
Dr. Mads Krogsgaard Thomsen	Exec. VP, Chief Science Officer & Member of the Management Board	N/A	N/A	1960
Mr. Henrik Ehlers Wulff	Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board	N/A	N/A	1970
Ms. Camilla Sylvest	Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board	N/A	N/A	1972

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate governance

Novo Nordisk A/S’s ISS governance QualityScore as of 7 December 2019 is 5. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 10; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.